Head-to-head comparison
| Property | Tesamorelin | Semaglutide |
|---|---|---|
| Category | Muscle & Growth | Weight Loss |
| Legal Status | Prescription | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~26-38 minutes | ~7 days |
| Mol. Weight | 5,135.89 Da | 4,113.58 Da |
| Side Effects | Injection site reactions (pain, redness), Joint pain, Nausea | Nausea (39%), Vomiting, Diarrhea |
Key differences
- Mechanism: Tesamorelin stimulates growth hormone release via GHRH receptors, specifically targeting visceral adipose tissue; semaglutide activates GLP-1 receptors to reduce appetite, slow gastric emptying, and promote overall weight loss.
- FDA-approved indication: Tesamorelin (Egrifta) is approved for HIV-associated lipodystrophy (excess abdominal fat); semaglutide (Wegovy) is approved for chronic weight management in obesity.
- Fat reduction pattern: Tesamorelin specifically reduces visceral (abdominal) fat with less effect on total body weight; semaglutide reduces total body weight including both visceral and subcutaneous fat.
- Dosing: Tesamorelin is dosed at 2 mg daily via subcutaneous injection; semaglutide is dosed at 0.25–2.4 mg weekly via subcutaneous injection.
- Weight loss magnitude: Semaglutide produces 15–17% total body weight loss; tesamorelin reduces trunk fat by approximately 18% but has modest effects on total body weight.
- Side effects: Tesamorelin may cause injection site reactions, joint pain, and peripheral edema; semaglutide primarily causes GI effects (nausea, vomiting, diarrhea).
- IGF-1 effects: Tesamorelin significantly increases IGF-1 levels (it stimulates GH); semaglutide does not directly affect the GH/IGF-1 axis.
The verdict
Tesamorelin and semaglutide address fat through fundamentally different pathways and are not interchangeable. Semaglutide is the more broadly applicable weight loss medication with superior total body weight reduction and established cardiovascular benefits. Tesamorelin is more specifically targeted at visceral fat accumulation and is FDA-approved for a specific population (HIV-associated lipodystrophy). The choice depends on whether the goal is overall weight loss (semaglutide) or targeted visceral fat reduction (tesamorelin).
Frequently asked questions
They work through entirely different pathways (GHRH vs GLP-1) and target different aspects of fat metabolism. Some clinical discussions have considered combination use, but no published clinical trials have studied this specific combination. Any such combination should be under direct physician supervision.
Tesamorelin specifically targets visceral (abdominal) fat and has demonstrated approximately 18% trunk fat reduction in trials. Semaglutide reduces total body weight (15–17%) which includes abdominal fat but is not visceral-fat-specific. For isolated visceral fat excess, tesamorelin is more targeted; for overall obesity, semaglutide is more effective.
Yes, tesamorelin is FDA-approved as Egrifta SV for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is a prescription medication. Its approved indication is narrower than semaglutide's (which is approved for general obesity management).
Tesamorelin primarily reduces visceral fat rather than total body weight. It produces modest overall weight loss compared to semaglutide. Semaglutide's mechanism (appetite suppression and slowed gastric emptying) produces substantially greater total body weight reduction.
Yes, tesamorelin is a GHRH analog that directly stimulates the pituitary gland to release growth hormone, which in turn raises IGF-1 levels. This GH elevation is the mechanism by which it reduces visceral fat. Semaglutide does not affect the GH/IGF-1 axis.